As mentioned in a previous post, the whole tech sector (including biotech), has largely been decimated the past 6+ months - in many instances irrespective of company performances. Commodities appear to have topped out and so hopefully there is a return of the market towards tech/ biotech.
The main thing is the business has continued to progress positively.
It took nearly 5 years to sell 5 instruments, and in the first period of this year alone (just over 4 months) 6 x instruments have been sold. Hopefully we see double digit sales in 2022 - there have been enough placements/ trials to see this as a realistic target.
The partnership with Thermo Fisher has started strong, and hopefully we see some traction with Beckman Coulter in Europe.
The continued development and broadening of APAS' capability over the past 12 months (Urine, MRSA, VRE, AST, Early Plate Reading) should all support continued growth.
APAS Sales
As mentioned in a previous post, the whole tech sector...
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
-0.002(12.5%) |
Mkt cap ! $18.77M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.6¢ | 1.4¢ | $20.63K | 1.387M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 164999 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 259001 | 1 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.5¢ |
Change
-0.002 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 1.5¢ | 1.5¢ | 1.5¢ | 288947 | ||
| Last updated 14.24pm 31/05/2024 ? | |||||
| LBT (ASX) Chart |